2. Academic Validation
  3. Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha

Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha

  • Nat Commun. 2025 Aug 22;16(1):7854. doi: 10.1038/s41467-025-62288-7.
Shilong Jiang # 1 2,  Keyi Liu # 3,  Ting Jiang # 4,  Hui Li 5,  Xiao Wei 5,  Xiaoya Wan 4,  Changxin Zhong 4,  Rong Gong 4,  Zonglin Chen 4 6,  Chan Zou 7,  Qing Zhang 3,  Yan Cheng 8 9,  Dongsheng Cao 10
Affiliations

Affiliations

  • 1 Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
  • 2 The Hunan Institute of Pharmacy Practice and Clinical Research, Changsha, Hunan, China.
  • 3 Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
  • 4 Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
  • 5 Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
  • 6 Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • 7 Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, China.
  • 8 Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China. yancheng@csu.edu.cn.
  • 9 Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China. yancheng@csu.edu.cn.
  • 10 Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China. oriental-cds@163.com.
  • # Contributed equally.
PMID: 40846852 DOI: 10.1038/s41467-025-62288-7
Abstract

Target identification in natural products plays a critical role in the development of innovative drugs. Bufalin, a compound derived from traditional medicines, has shown promising anti-cancer activity; however, its precise molecular mechanism of action remains unclear. Here, we employ artificial intelligence, molecular docking, and molecular dynamics simulations to elucidate the molecular mechanism of Bufalin. Using an integrated multi-predictive strategy, we identify CYP17A1, ESR1, mTOR, AR, and PRKCD as the potential targets of Bufalin. Subsequent validation via surface plasmon resonance, biotin pulldown, and thermal shift assays confirms Bufalin's direct binding to ESR1, which encodes Estrogen receptor alpha (ERα). Molecular docking analyses pinpoint Bufalin's selective interaction with Arg394 on ERα. Molecular dynamic simulations further show that Bufalin acts as a molecular glue, enhancing the interaction between ERα and the E3 Ligase STUB1, thereby promoting proteasomal degradation of ERα. Given the therapeutic potential of ERα degradation in overcoming endocrine resistance, we investigate the inhibitory effect of Bufalin on endocrine-resistant models and prove Bufalin reverses Tamoxifen resistance in vitro, in vivo, and in patient-derived breast Cancer organoids from tamoxifen-relapsed cases. Collectively, our findings indicate that Bufalin functions as a molecular glue to degrade ERα, offering a potential therapeutic strategy for reversing Tamoxifen resistance.

Figures
Products